In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

The FDA said the GSK drug shrank tumors in 41.6% of patients. Of those responders, 9.1% had a complete response while 32.5% showed a partial response. The median duration of response was 34.7 ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Now, it looks like GSK may have the edge in the U.S., securing priority review status from the FDA and an estimated decision date of May 3. GSK's RSV shot rises over peers with expected May ...

FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults. By Helen Branswell June 7, 2024. ... Prior to this FDA decision, Arexvy was licensed for use in people 60 and older.